Preparing HF validation reports that satisfy FDA reviewers for combination products


Preparing HF Validation Reports that Satisfy FDA Reviewers for Combination Products

Published on 04/12/2025

Preparing HF Validation Reports that Satisfy FDA Reviewers for Combination Products

The integration of human factors engineering (HFE) practices in the development of combination products is vital to ensure that the end users can safely and effectively use these products. In light of regulatory expectations set forth by the FDA, this article provides a comprehensive guide for regulatory professionals on how to prepare human factors validation reports that fulfill FDA reviewers’ criteria. Emphasis will also be placed on collaboration across various sectors including Chemistry, Manufacturing and Controls (CMC), Clinical, Pharmacovigilance (PV), Quality Assurance (QA), and Commercial teams.

Context

Human factors engineering is a discipline that optimizes the relationship between people and products through research and data-driven design principles. For combination products—defined as products combining a drug with a device or biological product—considering human factors is crucial to ensure usability, reduce risk, and enhance patient safety. Regulatory authorities like the FDA, EMA, and MHRA have established frameworks requiring that HFE principles be incorporated into product design and evaluation, explicitly included in submissions such as the human factors file and validation reports.

Legal/Regulatory Basis

In the US, the relevant guidelines concerning human factors

engineering and usability testing are established in several key documents:

  • FDA Guidance on Human Factors and Medical Devices (2016)
  • 21 CFR Part 820: Quality System Regulation, which mandates a quality system that assures the safety and efficacy of combination products.
  • FDA’s Combination Products: A Regulatory Overview, which outlines procedures and specifics regarding user-centered design that are mandatory for compliance.

In the EU, similar expectations are outlined in:

See also  Avoiding FDA findings on weak human factors files in combination product programs

Documentation Requirements

The documentation for human factors validation reports must demonstrate adherence to the guidelines and encompass several key components:

  1. Task Analysis: Identifying user tasks within the context of use and specifying critical tasks that require validation.
  2. User Profiles: Information on the intended users, including characteristics such as age, expertise, and experience level.
  3. Usability Testing: A detailed report of usability studies conducted, including test objectives, methodologies, results, and actions taken based on findings.
  4. Risk Assessment: Documentation of any usability-related risks and how they were mitigated through design adjustments.
  5. Labeling Information: Clear labeling that enhances usability and reduces potential misuse, which must be evaluated as part of the validation process.

The comprehensive preparation of these documents not only aligns with regulatory expectations but also demonstrates a thorough understanding of usability in the development process.

Review/Approval Flow

Understanding the FDA review and approval process is essential for regulatory professionals involved in submitting human factors validation reports. The key steps in the review and approval flow include:

  1. Pre-Submission Meeting: Engaging the FDA early in the development process can help clarify expectations and gather feedback on the proposed HFE studies.
  2. Submission of Human Factors Validation Report: Include the human factors file within the premarket submission (e.g., NDA, PMA, 510(k)), ensuring all relevant data and analyses are present.
  3. FDA Review: The FDA will assess usability data as a part of the substantial equivalence determination process, ensuring that products are not only effective but also safe for users.
  4. Response to Agency Queries: Be prepared to respond to questions or requests for additional data from the FDA, often arising from identified deficiencies or clarifications needed in the human factors data provided.
See also  On the job training OJT documentation and qualification sign off best practices

Common Deficiencies

Agencies such as the FDA frequently highlight common deficiencies seen during the review of human factors validation reports. Understanding these shortcomings can help regulatory affairs professionals preemptively address them:

  • Lack of Clarity in User Tasks: Clearly define what users need to do with the device or product. Ambiguities may lead to safety risks.
  • Insufficient User Feedback: Ensure usability tests include diverse populations to capture potential misuse or unanticipated user interactions.
  • Inadequate Risk Mitigation Strategies: Provide robust evidence of how usability-driven design iterations effectively mitigate identified risks.
  • Unclear Documentation: Documentation should be detailed and well-organized. An unclear submission can lead to misinterpretation by the review team.

Addressing these deficiencies before submission can significantly enhance the likelihood of a successful review process.

RA-Specific Decision Points

As regulatory professionals, understanding the various decision points in the submission process is critical. Below are key decision points that individuals in Regulatory Affairs should be aware of:

When to File as Variation vs. New Application

Determining whether to submit a variation or a new application (e.g., NDA vs. supplemental NDA) requires careful evaluation:

  • If changes impact safety and efficacy, a new application may be warranted.
  • If changes are solely focused on labeling or minor modifications that don’t affect key elements, a variation could suffice.

Justifying Bridging Data

Bridging data may be necessary when adapting human factors data from existing products to new submissions. It is important to:

  • Demonstrate that any differences between the former and current products do not significantly alter the user interactions.
  • Provide a strong rationale supported by user feedback and usability study results.
See also  Global alignment of FDA human factors engineering with EU MDR and UKCA requirements

Conclusion

Adhering to the FDA’s expectations for human factors engineering in combination products is crucial for successful regulatory compliance. By understanding the regulatory framework around human factors, preparing comprehensive documentation, and anticipating common deficiencies, regulatory professionals can navigate the complexities of submission processes more effectively. This proactive approach will not only facilitate smoother interactions with regulatory authorities but also enhance the overall safety and user experience of combination products in the marketplace.

Related Articles